Table 1.
Oligonucleotides used in this study.
Figure 1.
Optimization of mESC transfection.
A. pCas9-GFP expression plasmid was transfected into mESCs by the indicated method. GFP fluorescence was assessed by fluorescent microscopy and FACS. Numbers indicate the fraction of GFP-expressing cells. B. Percent of transfected cells and mean fluorescence intensity of GFP+ cells. n = 3. Graphs show mean ± s.e.m.
Figure 2.
Cas9 gene knockout using single or dual gRNAs.
A. mESC cell line L10a-GFP, in which one Rosa26 locus expresses GFP. B. Experimental outline and gRNAs. gRNAs #9 and #5 generate 5′ overhangs for dual nickase strategy. C. Single gRNA-directed GFP inactivation. D. Comparison of gRNA alone or gRNA+HDR donor containing a translational stop signal. n = 3. Bar = s.e.m. Red circles indicate individual data points. E. Gene inactivation frequency of single compared to paired gRNAs. F–G. Assessment of GFP expression in mESCs in the GFP-FACS fraction by fluorescent microscopy and western blotting. H. Effective gene knockout using dual gRNAs and the hCas9-D10A nickase mutant.
Figure 3.
Knockout of 3 congenital heart disease genes in mESCs.
A. Experimental outline. Paired gRNAs are designed to induce a deletion of about 100 bp. B. PCR genotyping of pooled ESC genomic DNA after Smad2 targeting. The mutant PCR product predominated. C. Surveyor nuclease on pooled ESC genomic DNA. Red arrowheads indicate nuclease cleavage products indicative of heterodimers. D. PCR genotyping of individual clones showing Smad2Δ/Δ, Smad2+/+, and Smad2+/Δ clones. E–F. Frequency of Smad2 genotypes amongst clonal outgrowths, after enrichment for transfected cells by GFP FACS or by transient puromycin selection. G. Western blot measurement of Smad2 expression in wild-type and Smad2Δ/Δ clones. H. Frequency of Mll2 genotypes amongst 39 genotyped clones. I. Confirmation of Mll2 inactivation in individual Mll2Δ/Δ clones by qRTPCR. J. Frequency of Chd7 genotypes amongst 48 genotyped clones. K. Confirmation of Chd7 inactivation in individual Chd7Δ/Δ clones by qRTPCR.
Figure 4.
Cas9-mediated introduction of a single base change.
A. Sap130 targeting strategy. The blue arrow indicates the gRNA targeting the reverse strand with the tail and tip representing the 5′ and 3′ ends, respectively. The HDR donor oligo is indicated by the green arrows. The T>C change is indicated in red. B. Surveyor nuclease assay on pooled ESC genomic DNA. Red arrowheads indicate nuclease cleavage products, diagnostic of heterodimers. C. Distribution of Sap130 mutations. D. Sequence chromatograms showing homozygous T>C mutation.
Figure 5.
Cas9-mediated targeted knockin.
A. Mef2c traditional targeting vector containing long homology arms, fl-bio epitope tag, and positive selection cassette. Efficiency of traditional and Cas9-mediated targeting strategies is shown. B. Cas9-mediated targeting using a 50 bp homology arms and no selectable marker. C. PCR genotyping of pooled ESC genomic DNA. Upper band is diagnostic of knockin. D. Confirmation of knockin and effective epitope tagging by streptavidin pulldown of in vivo biotinylated Mef2c. E. Cas9-mediated knockin of a longer insert. F. PCR genotyping of pooled ESC genomic DNA. The band is diagnostic of knockin. G. GFP expression after EB differentiation of a targeted clone.
Figure 6.
Effect of homology arm length for Cas9-mediated knockin.
A. GFP knockin at Oct4 C-terminus using 50 bp or 200 bp homology arms. Knockin efficiency was measured by FACS for GFP expression. B–C. GFP expression in GFP+ FACS clones by microscopy and western blotting. D. PCR genotyping of individual ESC clones. The PCR product (arrowhead) is diagnostic of knockin at Oct4.